Seeking Alpha

Alexion Pharmaceuticals (ALXN -1.2%) shrugs off the positive news earlier of Soliris getting...

Alexion Pharmaceuticals (ALXN -1.2%) shrugs off the positive news earlier of Soliris getting Orphan Drug status to trade lower, after Zack's cut the shares to Neutral from Outperform with a price target of $98. The firm says all the positive news on Soliris is already baked-in to the shares at present.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector